Published in J Invest Dermatol on March 24, 2014
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (2015) 3.29
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat Med (2015) 1.80
Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res (2014) 1.47
Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res (2015) 0.96
Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice and Humans. Cancer Prev Res (Phila) (2015) 0.89
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma. Nat Commun (2016) 0.85
Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget (2016) 0.83
DNA repair inhibition by UVA photoactivated fluoroquinolones and vemurafenib. Nucleic Acids Res (2014) 0.82
EphB2 Promotes Progression of Cutaneous Squamous Cell Carcinoma. J Invest Dermatol (2015) 0.82
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell (2016) 0.81
Oxidative Stress-Induced Protein Damage Inhibits DNA Repair and Determines Mutation Risk and Therapeutic Efficacy. Mol Cancer Res (2016) 0.81
Oxidative Damage to RPA Limits the Nucleotide Excision Repair Capacity of Human Cells. J Invest Dermatol (2015) 0.80
Fractionation of a tumor-initiating UV dose introduces DNA damage-retaining cells in hairless mouse skin and renders subsequent TPA-promoted tumors non-regressing. Oncotarget (2016) 0.80
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol (2016) 0.79
Frequent DPH3 promoter mutations in skin cancers. Oncotarget (2015) 0.78
Notch Cooperates with Survivin to Maintain Stemness and to Stimulate Proliferation in Human Keratinocytes during Ageing. Int J Mol Sci (2015) 0.77
Does Notch play a tumor suppressor role across diverse squamous cell carcinomas? Cancer Med (2016) 0.77
Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res (2015) 0.76
Novel CARD11 Mutations in Human Cutaneous Squamous Cell Carcinoma Lead to Aberrant NF-κB Regulation. Am J Pathol (2015) 0.76
Next-generation sequencing for mutation detection in heritable skin diseases: the paradigm of pseudoxanthoma elasticum. J Invest Dermatol (2015) 0.75
MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. J Invest Dermatol (2016) 0.75
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun (2016) 0.75
Late-Onset Multiple Self-Healing Squamous Epithelioma Ferguson-Smith Recurrence Induced by Radiotherapy. Case Rep Dermatol (2016) 0.75
Notch as a tumour suppressor. Nat Rev Cancer (2017) 0.75
Cutaneous HPV8 and MmuPV1 E6 Proteins Target the NOTCH and TGF-β Tumor Suppressors to Inhibit Differentiation and Sustain Keratinocyte Proliferation. PLoS Pathog (2017) 0.75
Loss of TGF-β signaling drives cSCC from skin stem cells - More evidence. Cell Cycle (2016) 0.75
Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors. Cancer (2016) 0.75
Whole exome sequencing validates a preclinical mouse model for the prevention and treatment of cutaneous squamous cell carcinoma. Cancer Prev Res (Phila) (2016) 0.75
Protein oxidation, UVA and human DNA repair. DNA Repair (Amst) (2016) 0.75
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol (2017) 0.75
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer (1953) 11.45
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A (1991) 6.42
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A (1996) 3.38
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A (2011) 3.10
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell (2012) 2.75
Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev (2007) 2.61
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest (1997) 2.30
Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst (1996) 2.28
Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol (2013) 2.25
Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell (2009) 2.19
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol (1992) 2.11
Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg (2002) 1.87
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med (2002) 1.86
Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog (1991) 1.70
Microsatellite instability in colorectal cancer. Br J Surg (2006) 1.46
Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol (2013) 1.38
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One (2013) 1.32
Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc Natl Acad Sci U S A (1993) 1.28
Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol (2009) 1.08
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa. Cancer Res (2012) 1.07
Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck (2007) 1.06
Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog (1991) 1.05
A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. Am J Transplant (2012) 1.02
Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes. Oncogene (1997) 1.02
A transposon-based analysis of gene mutations related to skin cancer development. J Invest Dermatol (2012) 0.98
High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res (1993) 0.94
Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol (2010) 0.94
Cytogenetic alterations in nonmelanoma skin cancer: a review. Genes Chromosomes Cancer (2005) 0.92
Expression of DNA mismatch repair proteins and MSH2 polymorphisms in nonmelanoma skin cancers of organ transplant recipients. Br J Dermatol (2009) 0.81
Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol (2013) 0.79
Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Mol Ther (2014) 0.97
CREBBP mutation in human cutaneous squamous cell carcinoma. Exp Dermatol (2016) 0.77
Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers. J Otolaryngol Head Neck Surg (2016) 0.75
Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget (2017) 0.75
Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies. Oncotarget (2017) 0.75
Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget (2017) 0.75